The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory

International Journal of Laboratory Hematology

Volumn 34, Issue 1, 2012, Pages 21-34

  Bench, A J ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Chimerism; Hematological malignancies; Minimal residual disease; Mutation detection; PCR clonality; Real time PCR

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN;

CLONAL VARIATION; FUSION GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MOLECULAR GENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW;

DNA MUTATIONAL ANALYSIS; GENETIC MARKERS; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; HEMATOLOGIC NEOPLASMS; HUMANS; ONCOGENE PROTEINS, FUSION; TRANSPLANTATION CHIMERA;

EID: 84155195246     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2011.01364.x     Document Type: Review

References (66)

1. Ahmadian A., Ehn M. & Hober S. (2006) Pyrosequencing: history, biochemistry and future. Clinica Chimica Acta 363, 83-94.
2. Alizadeh M., Bernard M., Danic B., Dauriac C., Birebent B., Lapart C., Lamy T., Le Prisé P.-Y., Beauplet A., Bories D., Semana G. & Quelvennec E. (2002) Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 99, 4618-4625.
3. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., Cervantes F., Deininger M., Gratwohl A., Guilhot F., Hochhaus A., Horowitz M., Hughes T., Kantarjian H., Larson R., Radich J., Simonsson B., Silver R.T., Goldman J. & Hehlmann R. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology 27, 6041-6051.
4. Beillard E., Pallisgaard N., van der Velden V.H.J., Bi W., Dee R., van der Schoot E., Delabesse E., Macintyre E., Gottardi E., Saglio G., Watzinger F., Lion T., van Dongen J.J.M., Hokland P. & Gabert J. (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 17, 2474-2486.
5. Bench A.J., Erber W.N., Follows G.A. & Scott M.A. (2007) Molecular genetic analysis of haematological malignancies II: mature lymphoid neoplasms. International Journal of Laboratory Hematology 29, 229-260.
6. Bench A., Boyd E., Manasse B., Bloxham D., Figueiredo de Sousa L., Scott M. & Erber W. (2010) Application of a novel melt curve assay for the detection of mutations within NPM1 exon 12. International Journal of Laboratory Hematology 32(Suppl 1) 59abstract.
7. Best O.G., Gardiner A.C., Majid A., Walewska R., Austen B., Skowronska A., Ibbotson R., Stankovic T., Dyer M.J.S. & Oscier D.G. (2008) A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 22, 1456-1459.
8. Bottcher S., Stilgenbauer S., Busch R., Bruggemann M., Raff T., Pott C., Fischer K., Fingerle-Rowson G., Dohner H., Hallek M., Kneba M. & Ritgen M. (2009) Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 23, 2007-2017.
9. Boyd E.M., Bench A.J., Goday-Fernandez A., Anand S., Vaghela K.J., Beer P., Scott M.A., Bareford D., Green A.R., Huntly B. & Erber W.N. (2010) Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. British Journal of Haematology 149, 250-257.
10. Childs R., Clave E., Contentin N., Jayasekera D., Hensel N., Leitman S., Read E.J., Carter C., Bahceci E., Young N.S. & Barrett A.J. (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94, 3234-3241.
11. Denys B., El Housni H., Nollet F., Verhasselt B. & Philippe J. (2010) A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide. Journal of Molecular Diagnostics 12, 512-519.
12. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., Dombret H., Fenaux P., Grimwade D., Larson R.A., Lo-Coco F., Naoe T., Niederwieser D., Ossenkoppele G.J., Sanz M.A., Sierra J., Tallman M.S., Lowenberg B. & Bloomfield C.D. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453-474.
13. van Dongen J.J.M., Langerak A.W., Bruggemann M., Evans P.A.S., Hummel M., Lavender F.L., Delabesse E., Davi F., Schuuring E., Garcia-Sanz R., van Krieken J.H.J.M., Droese J., Gonzalez D., Bastard C., White H.E., Spaargaren M., Gonzalez M., Parreira A., Smith J.L., Morgan G.J., Kneba M. & Macintyre E.A. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations. Leukemia 17, 2257-2317.
14. Dubovsky J., Daxberger H., Fritsch G., Printz D., Peters C., Matthes S., Gadner H., Lion T. & Muller-Bérat N. (1999) Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia 13, 2060-2069.
15. Evans P.A.S., Pott C., Groenen P.J.T.A., Salles G., Davi F., Berger F., Garcia J.F., van Krieken J.H.J.M., Pals S., Kluin P., Schuuring E., Spaargaren M., Boone E., Gonzalez D., Martinez B., Villuendas R., Gameiro P., Diss T.C., Mills K., Morgan G.J., Carter G.I., Milner B.J., Pearson D., Hummel M., Jung W., Ott M., Canioni D., Beldjord K., Bastard C., Delfau-Larue M.H., van Dongen J.J.M., Molina T.J. & Cabecadas J. (2007) Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21, 207-214.
16. Flohr T., Schrauder A., Cazzaniga G., Panzer-Grumayer R., van der Velden V., Fischer S., Stanulla M., Basso G., Niggli F.K., Schafer B.W., Sutton R., Koehler R., Zimmermann M., Valsecchi M.G., Gadner H., Masera G., Schrappe M., van Dongen J.J.M., Biondi A. & Bartram C.R. (2008) Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22, 771-782.
17. Gabert J., Beillard E., van der Velden V.H.J., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J.M., Cave H., Pane F., Aerts J.L.E., De Micheli D., Thirion X., Pradel V., Gonzalez M., Viehmann S., Malec M., Saglio G. & van Dongen J.J.M. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 17, 2318-2357.
18. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., Sanchez M.L., Nunez R., Prados A., Aldanondo I., Sanchez L., Dominguez M., Botana L.M., Sanchez-Jimenez F., Sotlar K., Almeida J., Escribano L. & Orfao A. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108, 2366-2372.
19. Gondek L.P., Tiu R., O'Keefe C.L., Sekeres M.A., Theil K.S. & Maciejewski J.P. (2008) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111, 1534-1542.
20. Grand F.H., Hidalgo-Curtis C.E., Ernst T., Zoi K., Zoi C., McGuire C., Kreil S., Jones A., Score J., Metzgeroth G., Oscier D., Hall A., Brandts C., Serve H., Reiter A., Chase A.J. & Cross N.C.P. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113, 6182-6192.
21. Gunn S.R., Mohammed M.S., Gorre M.E., Cotter P.D., Kim J., Bahler D.W., Preobrazhensky S.N., Higgins R.A., Bolla A.R., Ismail S.H., de Jong D., Eldering E., van Oers M.H., Mellink C.H., Keating M.J., Schlette E.J., Abruzzo L.V. & Robetorye R.S. (2008) Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. Journal of Molecular Diagnostics 10, 442-451.
22. Haferlach T., Kohlmann A., Wieczorek L., Basso G., Te Kronnie G., Bene M.-C., De Vos J., Hernandez J.M., Hofmann W.-K., Mills K.I., Gilkes A., Chiaretti S., Shurtleff S.A., Kipps T.J., Rassenti L.Z., Yeoh A.E., Papenhausen P.R., Liu W., Williams P.M. & Foa R. (2010) Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the international microarray innovations in leukemia study group. Journal of Clinical Oncology 28, 2529-2537.
23. Hagenkord J.M., Monzon F.A., Kash S.F., Lilleberg S., Xie Q. & Kant J.A. (2010) Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia. Journal of Molecular Diagnostics 12, 184-196.
24. Harrison C.N., Bareford D., Butt N., Campbell P., Conneally E., Drummond M., Erber W., Everington T., Green A.R., Hall G.W., Hunt B.J., Ludlam C.A., Murrin R., Nelson-Piercy C., Radia D.H., Reilly J.T., Van der Walt J., Wilkins B. & McMullin M.F. (2010) Guideline for investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology 149, 352-375.
25. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., van Hoomissen I.C., Goldman J.M. & Radich J.P. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine 349, 1423-1432.
26. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., Baccarani M., Cortes J., Cross N.C.P., Druker B.J., Gabert J., Grimwade D., Hehlmann R., Kamel-Reid S., Lipton J.H., Longtine J., Martinelli G., Saglio G., Soverini S., Stock W. & Goldman J.M. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108, 28-37.
27. Irving J.A.E., O'Brien S., Lennard A.L., Minto L., Lin F. & Hall A.G. (2004) Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib. Clinical Chemistry 50, 1233-1237.
28. Jimenez-Velasco A., Barrios M., Roman-Gomez J., Navarro G., Buno I., Castillejo J.A., Rodriguez A.I., Garcia-Gemar G., Torres A. & Heiniger A.I. (2005) Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms. Leukemia 19, 336-343.
29. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., Score J., Seear R., Chase A.J., Grand F.H., White H., Zoi C., Loukopoulos D., Terpos E., Vervessou E.C., Schultheis B., Emig M., Ernst T., Lengfelder E., Hehlmann R., Hochhaus A., Oscier D., Silver R.T., Reiter A. & Cross N.C. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106, 2162-2168.
30. Jones A.V., Cross N.C.P., White H.E., Green A.R. & Scott L.M. (2008) Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica 93, 1560-1564.
31. Kantarjian H., Schiffer C., Jones D. & Cortes J. (2008) Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111, 1774-1780.
32. Kittur J., Knudson R.A., Lasho T.L., Finke C.M., Gangat N., Wolanskyj A.P., Li C.Y., Wu W., Ketterling R.P., Pardanani A. & Tefferi A. (2007) Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109, 2279-2284.
33. Kohlmann A., Grossmann V., Klein H.-U., Schindela S., Weiss T., Kazak B., Dicker F., Schnittger S., Dugas M., Kern W., Haferlach C. & Haferlach T. (2010) Next generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS and RUNX1. Journal of Clinical Oncology 28, 3858-3865.
34. van Krieken J.H.J.M., Langerak A.W., Macintyre E.A., Kneba M., Hodges E., Garcia-Sanz R., Morgan G.J., Parreira A., Molina T.J., Cabecadas J., Gaulard P., Jasani B., Garcia J.F., Ott M., Hannsmann M.L., Berger F., Hummel M., Davi F., Bruggemann M., Lavender F.L., Schuuring E., Evans P.A.S., White H., Salles G., Groenen P.J.T.A., Gameiro P., Pott C. & van Dongen J.J.M. (2007) Improved reliability of lymphoma diagnostics via PCR-based clonality testing. Leukemia 21, 201-206.
35. Krypuy M., Ahmed A.A., Etemadmoghadam D., Hyland S.J., DeFazio A., Fox S.B., Brenton J.D., Bowtell D.D. & Dobrovic A. (2007) High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer 7, 168.
36. Langerak A.W., Molina T.J., Lavender F.L., Pearson D., Flohr T., Sambade C., Schuuring E., Al Saati T., van Dongen J.J.M. & van Krieken J.H.J.M. (2007) Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 21, 222-229.
37. Li J., Wang L., Janne P.A. & Makrigiorgos G.M. (2009) Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of Taqman-based real-time PCR. Clinical Chemistry 55, 748-756.
38. Lippert E., Girodon F., Hammond E., Jelinek J., Reading N.S., Fehse B., Hanlon K., Hermans M., Richard C., Swierczek S., Ugo V., Carillo S., Harrivel V., Marzac C., Pietra D., Sobas M., Mounier M., Migeon M., Ellard S., Kröger N., Herrmann R., Prchal J.T., Skoda R.C. & Hermouet S. (2009) Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 94, 38-45.
39. Liu H., Bench A.J., Bacon C.M., Payne K., Huang Y., Scott M.A., Erber W.N., Grant J.W. & Du M.-Q. (2007) A practical strategy for the routine use of BIOMED-2 PCR assays for detection of B- and T-cell clonality in diagnostic haematopathology. British Journal of Haematology 138, 31-43.
40. Lossos I.S., Czerwinski D.K., Alizadeh A.A., Wechser M.A., Tibshirani R., Botstein D. & Levy R. (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. New England Journal of Medicine 350, 1828-1837.
41. Lovisa F., Mussolin L., Corral L., Pillon M., Cazzaniga G., Biondi A. & Rosolen A. (2009) IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis. Laboratory Investigation 89, 1182-1186.
42. Maas F., Schaap N., Kolen S., Zoetbrood A., Buno I., Dolstra H., de Witte T., Schattenberg A. & van de Wiel-van Kemenade E. (2003) Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia 17, 621-629.
43. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., Fulton L.A., Locke D.P., Magrini V.J., Abbott R.M., Vickery T.L., Reed J.S., Robinson J.S., Wylie T., Smith S.M., Carmichael L., Eldred J.M., Harris C.C., Walker J., Peck J.B., Du F., Dukes A.F., Sanderson G.E., Brummett A.M., Clark E., McMichael J.F., Meyer R.J., Schindler J.K., Pohl C.S., Wallis J.W., Shi X., Lin L., Schmidt H., Tang Y., Haipek C., Wiechert M.E., Ivy J.V., Kalicki J., Elliott G., Ries R.E., Payton J.E., Westervelt P., Tomasson M.H., Watson M.A., Baty J., Heath S., Shannon W.D., Nagarajan R., Link D.C., Walter M.J., Graubert T.A., DiPersio J.F., Wilson R.K. & Ley T.J. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine 361, 1058-1066.
44. McMullin M.F., Reilly J.T., Campbell P., Bareford D., Green A.R., Harrison C.N., Conneally E. & Ryan K. (2007) Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. British Journal of Haematology 138, 821-822.
45. Mead A.J., Linch D.C., Hills R.K., Wheatley K., Burnett A.K. & Gale R.E. (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110, 1262-1270.
46. Milbury C.A., Li J. & Makrigiorgos G.M. (2009) PCR-based methods for the enrichment of minority alleles and mutations. Clinical Chemistry 55, 632-640.
47. Muller M.C., Merx K., Weiβer A., Kreil S., Lahaye T., Hehlmann R. & Hochhaus A. (2002) Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia 16, 2395-2399.
48. Noguera N.I., Ammatuna E., Zangrilli D., Lavorgna S., Divona M., Buccisano F., Amadori S., Mecucci C., Falini B. & Lo-Coco F. (2005) Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresisin acute myeloid leukemia. Leukemia 19, 1479-1482.
49. Oki Y., Jelinek J., Beran M., Verstovsek S., Kantarjian H.M. & Issa J.-P. (2006) Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 91, 1147-1148.
50. Olesen L.H., Clausen N., Dimitrijevic A., Kerndrup G., Kjeldsen E. & Hokland P. (2004) Prospective application of a multiplex reverse transcriptionpolymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single laboratory study of 390 paediatric and adult patients. British Journal of Haematology 127, 59-66.
51. Patel K.P., Pan Q., Wang Y., Maitta R.W., Du J., Xue X., Lin J. & Ratech H. (2010) Comparison of BIOMED-2 versus laboratory-developed polycmerase chain reaction assays for detecting T-cell receptor-γ gene rearrangements. Journal of Molecular Diagnostics 12, 226-237.
52. Press R.D., Willis S.G., Laudadio J., Mauro M.J. & Deininger M.W.N. (2009) Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 114, 2598-2605.
53. Rosenwald A., Alizadeh A.A., Widhopf G., Simon R., Davis R.E., Yu X., Yang L., Pickeral O.K., Rassenti L.Z., Powell J., Botstein D., Byrd J.C., Grever M.R., Cheson B.D., Chiorazzi N., Wilson W.H., Kipps T.J., Brown P.O. & Staudt L.M. (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. Journal of Experimental Medicine 194, 1639-1647.
54. Roti G., Rosati R., Bonasso R., Gorello P., Diverio D., Martelli M.F., Falini B. & Mecucci C. (2006) Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. Journal of Molecular Diagnostics 8, 254-259.
55. Schnittger S., Kern W., Tschulik C., Weiss T., Dicker F., Falini B., Haferlach C. & Haferlach T. (2009) Minimal residual disease levels assessed by NPM1 mutation specific RQ-PCR provide important prognostic information in AML. Blood 114, 2220-2231.
56. Shimoni A. & Nagler A. (2001) Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations. Leukemia 15, 1967-1975.
57. Sotlar K., Escribano L., Landt O., Mohrle S., Herrero S., Torrelo A., Lass U., Horny H.-P. & Bultmann B. (2003) One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. American Journal of Pathology 162, 737-746.
58. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J. & Vardiman J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France.
59. Thiede C., Bornhäuser M. & Ehninger G. (2004) Evaluation of STR informativity for chimerism testing - comparative analysis of 27 STR systems in 203 matched related donor recipient pairs. Leukemia 18, 248-254.
60. Tiacci E., Trifonov V., Schiavoni G., Holmes A., Kern W., Martelli M.P., Pucciarini A., Bigerna B., Pacini R., Wells V.A., Sportoletti P., Pettirossi V., Mannucci R., Elliott O., Liso A., Ambrosetti A., Pulsoni A., Forconi F., Trentin L., Semenzato G., Inghirami G., Capponi M., Di Raimondo F., Patti C., Arcaini L., Musto P., Pileri S., Haferlach C., Schnittger S., Pizzolo G., Foà R., Farinelli L., Haferlach T., Pasqualucci L., Rabadan R. & Falini B. (2011) BRAF mutations in hairy cell leukemia. New England Journal of Medicine 364, 2305-2315.
61. Valk P.J.M., Verhaak R.G.W., Beijen M.A., Erpelinck C.A.J., Barjesteh van Waalwijk van Doorn-Khosrovani S., Boer J.M., Beverloo H.B., Moorhouse M.J., van der Spek P.J., Löwenberg B. & Delwel R. (2004) Prognostically useful gene expression profiles in acute myeloid leukemia. New England Journal of Medicine 350, 1617-1628.
62. Vaughn C.P. & Elenitoba-Johnson K.S.J. (2004) High-resolution melting analysis for detection of internal tandem duplications. Journal of Molecular Diagnostics 6, 211-216.
63. van der Velden V.H.J., Boeckx N., Gonzalez M., Malec M., Barbany G., Lion T., Gottardi E., Pallisgaard N., Beillard E., Hop W.C.J., Hoogeveen P.G., Gabert J. & van Dongen J.J.M. (2004) Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease - a study within the Europe Against Cancer Program. Leukemia 18, 884-886.
64. Voelkerding K.V., Dames S.A. & Durtschi J.D. (2009) Next-generation sequencing: from basic research to diagnostics. Clinical Chemistry 55, 641-658.
65. Wang Y.L., Lee J.W., Kui J.S., Chadburn A., Cross N.C., Knowles D.M. & Coleman M. (2007) Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Acta Haematologica 118, 209-214.
66. Watzinger F., Lion T. & Steward C. (2006) The RSD code: proposal for a nomenclature of allelic configurations in STR-PCR-based chimerism testing after allogeneic stem cell transplantation. Leukemia 20, 1448-1452.